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Abstract 1 
Higher levels of circulating adiponectin have been related to lower risk of colorectal cancer in 2 
several prospective cohort studies, but it remains unclear whether this association may be causal. 3 
We aimed to improve causal inference in a Mendelian Randomization meta-analysis using nested 4 
case-control studies of the European Prospective Investigation into Cancer and Nutrition (EPIC, 5 
623 cases, 623 matched controls), the Health Professionals Follow-up Study (HPFS, 231 cases, 6 
230 controls) and the Nurses’ Health Study (NHS, 399 cases, 774 controls) with available data on 7 
pre-diagnostic adiponectin concentrations and selected single nucleotide polymorphisms (SNPs) 8 
in the ADIPOQ gene. We created an ADIPOQ allele score that explained approximately 3% of 9 
the interindividual variation in adiponectin concentrations. The ADIPOQ allele score was not 10 
associated with risk of colorectal cancer in logistic regression analyses (pooled OR per score-unit 11 
unit 0.97, 95% CI 0.91, 1.04). Genetically determined two-fold higher adiponectin was not 12 
significantly associated with risk of colorectal cancer using the ADIPOQ allele score as 13 
instrumental variable (pooled OR 0.73, 95% CI 0.40, 1.34). In a summary instrumental variable 14 
analysis (based on previously published data) with higher statistical power, no association 15 
between genetically determined two-fold higher adiponectin and risk of colorectal cancer was 16 
observed (0.99, 95% CI 0.93, 1.06 in women and 0.94, 95% CI 0.88, 1.01 in men). Thus, our 17 
study does not support a large causal effect of circulating adiponectin on colorectal cancer risk. 18 
Due to the limited genetic determination of adiponectin, larger Mendelian Randomization studies 19 
are necessary to clarify whether adiponectin is causally related to lower risk of colorectal cancer. 20 
 21 
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Background 1 
Obesity, in particular abdominal obesity is an established risk factor for the development of 2 
colorectal cancer (1). Although the underlying biological mechanisms have not been fully 3 
elucidated, it is widely accepted that the adipose tissue, particularly visceral adipose tissue, is an 4 
active endocrine organ secreting various bioactive substances collectively named adipokines, 5 
which may provide an important link between body fatness and colorectal cancer risk (2). In 6 
contrast to many other adipokines, adiponectin expression is suppressed in obesity and plasma 7 
concentrations are lower in obese than in lean individuals (3). Adiponectin has been suggested to 8 
play a protective role in the development of cancer either directly through inhibition of cell 9 
growth (e.g. via RAS signaling(4)) and induction of apoptosis, or indirectly through improved 10 
insulin sensitivity and reduced inflammation(5). The association between circulating adiponectin 11 
concentrations and risk of colorectal cancer has been investigated in several prospective cohort 12 
studies, with mixed findings: Higher plasma adiponectin concentrations were associated with 13 
lower risk of colorectal cancer (slightly stronger in women than men, but no statistically 14 
significant sex-differences) in the European Prospective Investigation into Cancer and Nutrition 15 
(EPIC) (6) and in the Health Professionals Follow-up study (HPFS), while no association was 16 
observed in the Nurses’ Health Study (NHS)(7). A meta-analysis of ten case-control or nested 17 
case-control studies (not including the data from EPIC, NHS or HPFS) reported a statistically 18 
significant two percent lower risk of colorectal cancer or adenoma for a 1 µg/mL increment in 19 
adiponectin in men whereas among women no association was observed(8). 20 
To date, it remains unclear whether adiponectin plays a causal role in the development of colorectal 21 
cancer not least because it cannot be excluded that residual confounding and/or reverse causation 22 
bias might have introduced bias in observational associations (Figure 1). Mendelian 23 
Randomization is a statistical approach that can improve causal inference(9). The principle is that 24 
under the assumption of the random assortment of alleles at conception, genetic variants that are 25 
associated with biomarker levels can be used as relatively unbiased proxies for biomarker 26 
concentrations due to two advantages. First, since the genotype of an individual is determined at 27 
gamete formation and cannot be altered later on (e.g. by disease onset), there is no possibility of 28 
reverse causation(10). Second, the relationship between genetic variants and disease risk can be 29 
assumed to be not confounded by lifestyle and behavioral factors that can confound the observed 30 
association between circulating biomarkers and risk of disease. Therefore, using genetic variants 31 
associated with circulating biomarker concentrations in a Mendelian Randomization approach may 32 
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provide insight into the underlying causal relationships by circumventing reverse causation and 1 
residual confounding. In a pooled analysis from the Genetics and Epidemiology of Colorectal 2 
Cancer Consortium (GECCO), which includes data from NHS, HPFS and eight other studies 3 
comprising overall more than 7,000 colorectal cancer cases and approximately the same number 4 
of controls, genetic variants in the gene encoding adiponectin (ADIPOQ) were not associated with 5 
colorectal cancer risk(11). However, a simultaneous analysis of adiponectin concentrations, 6 
ADIPOQ genetic variants and colorectal cancer was not conducted, because adiponectin plasma 7 
levels were only available in a subset of included studies, namely NHS and HPFS. With a dataset 8 
including individual participant data on genetic variants, biomarker concentration and disease 9 
outcome, a traditional Mendelian Randomization analysis taking into account the actual strength 10 
of the association between ADIPOQ-SNPs and adiponectin concentrations in the study population 11 
can be performed, which has the advantage that instrumental variable assumptions can be directly 12 
assessed (12, 13). The aim of our investigation was therefore to improve causal inference in the 13 
association between circulating adiponectin and colorectal cancer risk using ADIPOQ genetic 14 
variants in a Mendelian Randomization meta-analysis with individual participant data from the 15 
EPIC, HPFS and NHS cohorts. 16 
 17 
Methods 18 
 19 
Study population 20 
The three studies included in the present investigation were all nested case-control studies of large 21 
prospective cohorts with long follow-up. In all nested case-control studies, colorectal cancer was 22 
defined according to the International Statistical Classification of Diseases, Injury and Causes of 23 
Death (ICD-10) as cancers of the colon (C18.0-C18.7), cancers of the rectum (C19-C20) and 24 
tumors that were overlapping or unspecified (C18.8-C18.9). Blood samples were collected prior to 25 
diagnosis and matched control participants were selected using incidence density sampling, i.e. 26 
selection was performed among study participants who were alive and free of cancer (except non-27 
melanoma skin cancer) at the time of diagnosis of the colorectal cancer case. 28 
The EPIC study is a large multicenter prospective cohort including more than 520,000 study 29 
participants from 10 European countries who were aged between 35 and 70 years at recruitment 30 
which took place from 1992 to 2000(14). Baseline examinations included anthropometric 31 
measurements, standardized ascertainment of lifestyle characteristics and medical history 32 
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information as well as collection of blood samples. The EPIC study was approved by the ethical 1 
review board of the International Agency for Research on Cancer (IARC, Lyon, France) and the 2 
institutional review boards of each participating study center and informed consent was obtained 3 
from all participants. Incident cancer cases including colorectal cancer cases were determined 4 
through record linkage with local cancer registries in most countries (Denmark, Naples (Italy 5 
except), the Netherlands, Norway, Spain, Sweden, United Kingdom, complete up to 2003). In some 6 
countries (France, Germany, Naples (Italy), Greece, complete up to 2002) active follow-up was 7 
organized by contact of participants or next of kin through mailed questionnaires, followed by 8 
verification of self-reported cases by study physicians using health insurance data, data from cancer 9 
and clinical registries as well as medical records provided by the treating physicians. In the present 10 
analysis, colorectal cancer cases with available prediagnostic blood samples and DNA were 11 
included. As has been described previously(6), the nested case-control design matched each case 12 
to one control using incidence density sampling. Control participants were selected matched on age 13 
at blood collection (2 months to 4-year intervals), study center, fasting status (<3, 3-6, or>6 hours) 14 
as well as menopausal status and hormone use in women. The nested case-control study was 15 
designed to be applicable for several biomarker studies, which explains inclusion of the latter 16 
matching criteria which were not relevant for the present analysis. The number of cases and 17 
matched controls included in the present study is 1,246 (623 cases, 623 matched controls) which 18 
is 52% of the study size of the previous analysis on circulating adiponectin and risk of colorectal 19 
cancer in EPIC (1,206 cases, 1,206 matched controls) (6). This difference is largely explained by 20 
unavailability of DNA samples from the Danish EPIC centers due to local technical and 21 
organizational issues.   22 
 23 
The HPFS and NHS are two large US cohort studies, detailed descriptions of which are provided 24 
elsewhere (15, 16). In brief, the HPFS started in 1986, including 51,529 men aged 40-75 years, and 25 
the NHS started in 1976 and included 121,701 women aged 30-55 years. In both cohorts, study 26 
participants provided information on medical history and lifestyle at recruitment. Since then, 27 
follow-up questionnaires were administered biennially to collect and update medical and lifestyle 28 
information and to elicit medical diagnoses. The follow-up rates in both cohorts exceeded 90% in 29 
each 2-year cycle and the cumulative follow-up rate (percentage of potentially collected person-30 
years) was 94% in HPFS and 93% in NHS. Blood specimens were provided by 18,225 HPFS 31 
participants (35%) between 1993 and 1995 and by 32,826 NHS participants (27%) between 1989 32 
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and 1990 by overnight courier. Details on the procedures of blood collection as well as handling 1 
and storage of blood samples have been described previously(17, 18). Among the participants for 2 
whom blood samples and DNA were available, 231 colorectal cancer cases were confirmed after 3 
blood collection in HPFS (up to January 1st 2008) and 399 in NHS (up to October 1st 2008). For 4 
each case up to two controls were randomly selected using incidence density sampling. The 5 
majority of individuals included in the nested case-control studies were of Caucasian ancestry in 6 
both HPFS (95.5%) and NHS (99.9%). All study participants provided informed consent and the 7 
study protocol was approved by the Institutional Review Board of the Brigham and Women’s 8 
Hospital and the Harvard T.H. Chan School of Public Health.  9 
The total number of participants in the present investigation is 2,880 (1,253 cases and 1,627 10 
controls), including 1,246 in EPIC (623 cases and 623 controls), 461 in HPFS (231 cases, 230 11 
controls) and 1,173 in NHS (399 cases, 774 controls). 12 
 13 
 14 
Adiponectin measurement 15 
Total circulating adiponectin concentration was measured using enzyme-linked immunosorbent 16 
assays from ALPCO Diagnostics (Salem, New Hampshire) in the three studies (6, 7). Based on 17 
quality control samples, interbatch coefficients of variation were 8.3% in EPIC and 8.6% in HPFS 18 
and NHS. Adiponectin measurements in n=300 paired samples from HPFS showed high reliability, 19 
with intraclass correlation coefficient of 0.85 when measured within the same persons one year 20 
apart (19).  21 
 22 
SNP selection and genotyping 23 
In EPIC, a set of tagging SNPs covering variations in the ADIPOQ gene in populations of 24 
European ancestry was selected using HapMap 22/phase II CEPH population data (Utah residents 25 
with northern and western European descent) applying stringent criteria (minor allele frequency 26 
>5% and pairwise r2≥0.8). A total number of 15 SNPs were genotyped using TaqMan 27 
methodology (genotype call rates >99.2% for all the assays), of which one (rs7649121) was not 28 
in Hardy-Weinberg equilibrium in control participants (p<0.0001) and therefore was excluded 29 
from analysis. In HPFS and NHS SNPs in the ADIPOQ gene were selected based on previous 30 
evidence from genome-wide association studies (GWAS) on circulating adiponectin 31 
concentrations (20-23). Additional SNPs in adiponectin-related genes that have been associated 32 
10 
 
with colorectal cancer risk were genotyped (24-26). A total of 19 SNPs were genotyped using 1 
Illumina HumanOmniExpress as part of the GECCO project (11). Missing SNPs were imputed to 2 
HapMap II release 24. All genotyped SNPs were in Hardy-Weinberg equilibrium in control 3 
participants. Eight ADIPOQ SNPs were available in all three included studies (rs1063539, 4 
rs16861194, rs822394, rs17300539, rs17366568, rs17366743, rs266729, rs1501299) and minor 5 
allele frequencies were comparable.  6 
 7 
Statistical analysis 8 
We created an ADIPOQ allele score that was used to derive Mendelian Randomization estimates 9 
using two different approaches: Firstly, we analyzed the ADIPOQ allele score in relation to 10 
colorectal cancer risk. Secondly, we applied an instrumental variable approach, simultaneously 11 
incorporating ADIPOQ genetic variation and plasma adiponectin concentrations, to model the 12 
association between genetically determined circulating adiponectin and colorectal cancer risk. 13 
While the first approach, which is considered as an equivalent to the intention-to-treat analysis in 14 
a randomized controlled trial (27), can only test for the existence of a causal association, the 15 
second approach aims at estimating the magnitude of a causal association (e.g. risk estimate per 16 
2-fold higher genetically determined adiponectin) (28).  17 
 18 
ADIPOQ allele score 19 
The weighted ADIPOQ allele score was constructed by summing alleles that have been 20 
associated with higher adiponectin with genome-wide significance in a previous meta-analysis of 21 
GWAS on adiponectin levels, using their GWAS-coefficients as weights (20). Only SNPs not 22 
highly correlated (r2<0.8) were included in the score. For NHS and HPFS, the included SNPs 23 
were rs17300539, rs17366568, rs266729, rs1501299 and rs6810075. The score in EPIC was built 24 
using the same SNPs, except that for rs6810075 the proxy SNP rs182052 was used. To examine 25 
whether the ADIPOQ allele score is independent of potentially confounding factors, we 26 
compared baseline characteristics in each study across score categories (approximate tertiles).  27 
 28 
The associations between the individual ADIPOQ SNPs as well as the ADIPOQ allele score and 29 
adiponectin concentrations were examined using linear regression models with robust variance in 30 
control participants (29). Adiponectin concentrations were naturally log-transformed (because of 31 
skewed distribution) and we calculated the estimated relative change in percent in adiponectin per 32 
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minor allele (with genotypes coded 0, 1 or 2 according to the number of variant alleles) or per 1 
score unit, respectively. In addition, R2 and F-values as measures of instrument strength are 2 
presented. In the previous publication by Song et al. (11) the association between ADIPOQ SNPs 3 
and plasma adiponectin concentrations was presented for HPFS and NHS, but the here included 4 
colorectal cancer controls were only a small subset of the individuals included in that analysis.  5 
Association between ADIPOQ allele score and colorectal cancer  6 
The association between the ADIPOQ allele score (per score-unit) in relation to risk of colorectal 7 
cancer was calculated in each study. In EPIC, we used conditional logistic regression 8 
conditioning on the matching variables and calculating odds ratios (ORs) and 95% confidence 9 
intervals that approximate incidence rate ratios and can be interpreted as relative risks.  In HPFS 10 
and NHS, we used unconditional logistic regression adjusted for matching variables (age at blood 11 
draw and date of blood draw) to estimate relative risks. In sensitivity analyses, we restricted the 12 
logistic regression models to individuals with Caucasian ancestry (n=16 excluded in HPFS and 13 
n=1 excluded in NHS). Because multivariable adjustment is per definition not required in 14 
Mendelian Randomization studies, only minimally adjusted (conditional logistic regression 15 
conditioned on the matching variables or unconditional logistic regression adjusted for matching 16 
factors) estimates are presented. We pooled the study-specific results using a meta-analytic 17 
approach with random effects (30), thereby also assessing potential heterogeneity across studies.  18 
Instrumental variable analysis 19 
For the joint analysis of adiponectin concentrations, genetic variants of the ADIPOQ gene and 20 
colorectal cancer risk, we performed an instrumental variable analysis using two-stage regression. 21 
In the first stage, adiponectin concentrations were predicted based on the ADIPOQ allele score by 22 
means of linear regression. In order to avoid potential bias (31), the first stage regression was 23 
performed only in control participants and genetically determined adiponectin was predicted for 24 
the total study population including participants without measured adiponectin. In the second 25 
stage, a logistic regression of colorectal cancer on the predicted adiponectin concentrations was 26 
performed in each study. In EPIC, the second stage was a conditional logistic regression 27 
appropriate for the matched design, whereas in HPFS and NHS, the second stage was an 28 
unconditional logistic regression adjusted for matching factors. For HPFS and NHS, we restricted 29 
instrumental variable analyses to individuals of Caucasian ancestry in sensitivity analyses. The 30 
risk estimates resulting from the instrumental variable analysis display the association between 2-31 
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fold genetically determined higher adiponectin in relation to risk of colorectal cancer. Pooled 1 
associations were determined using random effects model and potential heterogeneity was 2 
assessed. We tested whether the causal risk estimates of the individual SNPs included in the 3 
ADIPOQ allele score were of similar magnitude using an over-identification test.  Finally, to 4 
increase statistical power, we performed a summary instrumental variable analysis using 5 
published data (13).  Parameters for the association between the SNPs included in the ADIPOQ 6 
allele score and circulating adiponectin were taken from GWAS data (20) and parameters for the 7 
association between the SNPs and colorectal cancer were derived from the analysis in GECCO 8 
(11). Because summary instrumental variable analysis can be biased when correlated SNPs are 9 
included, we omitted rs266729 from this analysis, because it is in linkage disequilibrium with 10 
rs6810075 (r2 0.5). 11 
All statistical tests are two-sided with significance at the 5% level. Instrumental variable analyses 12 
were performed using the STATA SE 12 (StataCorp, College Station, Texas, USA). Summary 13 
instrumental variable analyses were performed with a publicly available R-Studio application 14 
(Foundation for Statistical Computing, Vienna, Austria).  All other analyses were performed 15 
using SAS (for EPIC data: SAS Enterprise Guide 4.3; for HPFS and NHS data: SAS 9.3; SAS 16 
Institute Inc., Cary, North Carolina, USA).  17 
 18 
Results 19 
Baseline characteristics of study participants in EPIC, HPFS and NHS are displayed in table 1. In 20 
EPIC and HPFS, incident colorectal cancer cases had a statistically significantly higher body 21 
mass index (BMI) and waist circumference than controls at baseline, whereas in NHS, these 22 
anthropometric measures did not differ between case and control participants. In EPIC, colorectal 23 
cancer cases consumed more alcohol and red and processed meat than control participants, 24 
whereas in the US cohorts, no such differences were observed. Other potentially confounding 25 
factors including physical activity and fiber intake did not differ remarkably between cases and 26 
controls in any study. In EPIC and HPFS, but not in NHS, adiponectin concentrations were lower 27 
in cases than in control participants in univariate comparisons.  28 
Of the 14 ADIPOQ SNPs available for analysis in EPIC, five SNPs were statistically significantly 29 
associated with circulating adiponectin (Table 2). Each unit of the GWAS-based ADIPOQ allele 30 
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score was associated with 6.5 % (95% CI 3.6, 9.4) higher adiponectin. The ADIPOQ allele score 1 
explained 3.2% of the interindividual variation in adiponectin concentrations (F-value 20.2). In 2 
HPFS, three of the 19 genotyped SNPs were statistically significantly associated with adiponectin 3 
concentrations (Table 3). Each unit of the ADIPOQ allele score was associated with 7.7 % (95% 4 
CI 0.9, 14.9)  higher adiponectin (F-value 5.0). In NHS, six of the 19 available SNPs were 5 
statistically significantly associated with circulating adiponectin. The ADIPOQ-score was 6 
associated with 7.7 % (95% CI 4.1, 11.3) higher adiponectin concentrations and explained 3.6% 7 
of the interindividual variation in circulating adiponectin (F-value 14.2).  8 
Potentially confounding factors assessed in the three cohorts did not differ remarkably across 9 
categories (approximate tertiles) of the external ADIPOQ-score (all P-values >0.05, supplemental 10 
table 1).  11 
The ADIPOQ allele score was not statistically significantly associated with risk of colorectal 12 
cancer (pooled OR per score-unit 0.97, 95% CI 0.91, 1.04) in logistic regression analysis (table 13 
4). This result was not altered when logistic regression analyses were restricted to Caucasian 14 
individuals in HPFS and NHS (pooled OR 0.97, 95% CI 0.91, 1.04).  In the instrumental variable 15 
analysis taking measured adiponectin and ADIPOQ genetic variation in our study population 16 
simultaneously into account (table 5), using the ADIPOQ allele score as instrumental variable,, 17 
genetically determined two-fold higher adiponectin was not statistically significantly associated 18 
with lower risk of colorectal cancer (pooled OR 0.73, 95% CI 0.40, 1.34). These associations 19 
were not altered by restriction to Caucasians in HPFS and NHS (pooled OR 0.73, 95% CI 0.41, 20 
1.33). Over-identification tests suggested that the effects of all SNPs included in the ADIPOQ 21 
allele score were similar with respect to colorectal cancer risk in all three studies (P-values were 22 
0.64 in EPIC, 0.81 in HPFS and 0.52 in NHS). 23 
In the summary instrumental variable analysis using published data (GWAS on adiponectin(20); 24 
associations of ADIPOQ-SNPs with colorectal cancer published by the GECCO consortium(11)), 25 
no association between genetically determined higher adiponectin and risk of colorectal cancer 26 
was observed (OR per 2-fold higher adiponectin 0.99, 95% CI 0.93, 1.06 in women and 0.94, 27 
95% CI 0.88, 1.01 in men) using the four SNPs rs1730539, rs17366568, rs1501299 and 28 
rs6810075 as instruments.   29 
Discussion 30 
14 
 
In this Mendelian Randomization analysis using data from three nested case-control studies of 1 
large prospective cohorts, we did not find evidence for a causal contribution of high adiponectin 2 
levels to lower risk of colorectal cancer. However, adiponectin concentrations were genetically 3 
determined only to a limited extent, which limited statistical power for our Mendelian 4 
Randomization analysis.  5 
 6 
In a genetic association meta-analysis, the minor alleles of three ADIPOQ SNPs (rs1501299, 7 
rs2241766, rs266729) were associated with colorectal cancer risk (32), but associations were only 8 
seen in Asians and not in Caucasians. Individual SNPs at the ADIPOQ loci, including those 9 
incorporated in the ADIPOQ allele score in the present study (rs17300539, rs17366568, 10 
rs17366743, rs1501299, rs3774261 (the proxy SNPs rs2241766 was used in GECCO), 11 
rs6810075, rs266729, rs6773957, rs6444175, rs1063538) were unrelated to risk of colorectal 12 
cancer in GECCO (11). In the same study, the allele-sum of 16 SNPs that have been related to 13 
higher adiponectin concentrations in previous GWAS were combined in a genetic score, which 14 
was not related to colorectal cancer risk in women (OR per ten-allele increment 1.08, 95% CI 15 
0.95, 1.22) or men (OR 1.01, 95% CI 0.90, 1.13). In contrast, in a two-sample Mendelian 16 
Randomization meta-analysis (33) using the ADIPOQ SNP rs2241766 as instrumental variable, 1 17 
mg/L genetically determined higher adiponectin was associated with a 20-40% higher risk of 18 
colorectal cancer.  19 
The strength of our study is the ability to jointly investigate adiponectin, genetic variation in the 20 
ADIPOQ gene and risk of colorectal cancer. In contrast to a two-sample Mendelian 21 
Randomization design, a full sample design, where genetic information and intermediate 22 
phenotype data (i.e. measured adiponectin concentration) are available in the same study 23 
participants, generally requires less assumptions and allows for systematic evaluation of 24 
instrumental variable assumptions (34). Thus, we were able to estimate the strength of the 25 
association between the ADIPOQ SNPs as well as the ADIPOQ allele score and adiponectin 26 
concentrations in our sample, thereby showing that the first Mendelian Randomization 27 
assumption was fulfilled. Furthermore, we showed that potentially confounding lifestyle factors 28 
did not vary substantially across categories of the instrumental variable, i.e. the second 29 
Mendelian Randomization assumption was also satisfied (35). It should be noted that only 30 
potentially confounding factors measured in the three studies could be investigated, thus, it 31 
15 
 
cannot be entirely excluded that unmeasured confounders varied by categories of the ADIPOQ 1 
allele score. Assessment of the third Mendelian Randomization assumption (instrumental variable 2 
is associated with the outcome only through the intermediate exposure of interest, i.e. no 3 
pleiotropy) is not as straightforward, but the use of multiple SNPs as instrumental variables argue 4 
against unknown pleiotropy given that all genetic variants have a similar effect on the outcome, 5 
which was confirmed in our samples by the non-significant over-identification test results. 6 
Furthermore, the genetic variants used as instrumental variables were restricted to the ADIPOQ 7 
gene and therefore likely act directly on the adiponectin trait, which argues also against 8 
pleiotropic effects (27).  9 
However, our study has also several limitations: Given the limited genetic determination of 10 
adiponectin concentrations, our sample sizes from three nested case-control studies of 11 
prospective cohorts was limited to derive robust causal estimates. The ADIPOQ-score applied 12 
here explained only a low proportion (2.9%-3.6%) of the interindividual variation in adiponectin 13 
concentrations. With this genetic instrument and our sample size, the minimal OR that could have 14 
been detected with 80% statistical power was 0.61 per standard deviation in adiponectin, which is 15 
a stronger association than has been observed in most observational studies (8). Even with the 16 
relatively large sample size in GECCO (7,020 cases, 7,631 controls) no association between a 17 
genetic score of variants associated with adiponectin and colorectal cancer was detected(11). 18 
Furthermore, in our summary data instrumental variable analysis, genetically determined higher 19 
adiponectin was not associated with colorectal cancer risk (minimal detectable OR with 80% 20 
power: 0.76 per standard deviation in adiponectin). A much larger sample size (n=33,960 cases, 21 
33,960 controls) would be necessary to detect a moderate effect (e.g. OR 0.89 per 1 SD as 22 
observed in EPIC(6)) of adiponectin and colorectal cancer. Therefore, with our study and the 23 
summary instrumental variable analysis based on GECCO, we cannot rule out causality in the 24 
association between circulating adiponectin and risk of colorectal cancer. Although it has been 25 
suggested that the 2-stage instrumental variable estimator may result in biased estimates under 26 
case-control sampling, it has been shown to be unbiased under the null hypothesis of no causal 27 
effect as in the present study (36). 28 
In conclusion, this Mendelian Randomization meta-analysis using data from three nested case-29 
control studies of prospective cohorts does not support a large causal effect of circulating 30 
adiponectin on colorectal cancer risk. This lack of association may be related to the limited 31 
16 
 
genetic determination of adiponectin and the limited sample size. Therefore, larger Mendelian 1 
Randomization studies are necessary to clarify whether adiponectin is causally related to lower 2 
risk of colorectal cancer. 3 
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Overview of figures and tables 1 
 2 
 3 
Figure 1. Directed acyclic graph (DAG) for Mendelian Randomization Study on adiponectin and 4 
colorectal cancer risk.  5 
Table 1 Baseline characteristics of study participants in EPIC, HPFS and NHS 6 
Table 2 Association between all ADIPOQ SNPs genotyped in EPIC and plasma adiponectin 7 
levels in control participants (n=623) 8 
Table 3 Association between all ADIPOQ SNPs genotyped in NHS and HPFS and plasma 9 
adiponectin levels in control participants (n=167 in HPFS, n=510 in NHS)    10 
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Table 4. Association between internal and external ADIPOQ-scores in EPIC, HPFS, and NHS 12 
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Table 5. Instrumental variable estimation of the association between genetically determined 14 
adiponectin concentrations with risk of colorectal cancer in EPIC, HPFS, and NHS 15 
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 1 
 2 
Figure 1. Directed acyclic graph (DAG) for Mendelian Randomization Study on adiponectin and 3 
colorectal cancer risk. X: modifiable exposure of interest; Y: outcome; C: confounder(s); Z: instrumental 4 
variable. NOTE: The effect of Z on Y should be mediated only through X (no pleiotropy), therefore this 5 
line is dashed. Associations [ZX] and [ZY] are used to estimate the causal effect of a biomarker on an 6 
outcome circumventing residual confounding and reverse causation. 7 
   8 
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Table 1 Baseline characteristics of study participants in EPIC, HPFS and NHS 
 EPIC (n=1,246)§ HPFS (n=461)$ NHS (n=1173)$ 
 Controls (n=623) Cases (n=623) P a Controls (n=230) Cases (n=231) Pb Controls (n=774) Cases (n=399) Pb 
Female sex, n (%) 289 (46.4) 289 (46.4) * 0 (0) 0 (0)  771 (100) 398 (100)  
Age at blood collection, 
years, mean (SD) 
58.3 (8.2) 58.3 (8.2) * 65.6 (8.9) 66.1 (8.8) * 59.1 (6.7) 59.2 (6.7) * 
Current smoking, n (%) 124 (19.9) 122 (19.6) 0.88 12 (5.4) 8 (3.6) 0.35 90 (11.7) 48 (12.1) 0.85 
Caucasian ethnicity, n (%) n.a. n.a. n.a. 226 (98.3) 219 (94.8) 0.04 773 (99.9) 399 (100) 0.47 
Physical activity (MET-
hours/week), mean (SD) 
89.1 (52.1) 90.4 (54.8) 0.59 34.5 (29.2) 35.8 (41.3) 0.70 16.4 (19.8) 16.5 (19.2) 0.88 
Body mass index, kg/m2, 
mean (SD) 
26.4 (3.8) 27.1 (4.4) 0.001 25.2 (3.3) 26.0 (3.1) 0.004 25.4 (4.4) 25.3 (4.3) 0.72 
Waist circumference, cm, 
mean (SD) 
89.3 (12.3) 91.9 (13.1) <0.0001 94.2 (9.4) 96.8 (8.4) 0.004 79.5 (10.7) 80.3 (10.9) 0.41 
Alcohol intake, g/day, 
median (IQR) 
6.4 
(1.0-21.1) 
7.8 
(0.8-22.6) 
0.02 
7.0 
(1.8-15.8) 
6.9 
(0.9-18.7) 
0.86 
1.1 
(0.0- 6.9) 
1.8 
(0.0- 8.5) 
0.07 
Fiber, g/day, median (IQR) 
21.8 
(17.7-27.0) 
21.5 
(16.8-27.5) 
0.77 
22.7 
(18.6-28.8) 
22.2 
(18.4-27.2) 
0.34 
18.1 
(15.1-21.3) 
17.7 
(15.2-21.1) 
0.34 
Red and processed meat, 
g/day, median (IQR) 
69.1 
(45.4-101.5) 
72.3 
(49.4-108.8) 
0.02 
63.4 
(33.5-98.1) 
64.5 
(37.5-105.5) 
0.20 
52.4 
(33.4-81.2) 
55.8 
(33.4-91.7) 
0.23 
          
Total adiponectin (μg/mL), 
median (IQR)c 
6.3 
(4.8- 8.7) 
5.9 
(4.3- 8.2) 
0.01 
5.6 
(3.9- 8.2) 
5.3 
(3.5- 7.2) 
0.21 
8.5 
(6.0-11.0) 
8.5 
(6.0-11.5) 
0.64 
 
 
SD, standard deviation, IQR, inter-quartile range, MET, metabolic equivalent of task       
aP-values for the difference between cases and controls were determined by Mc Nemar's test for variables expressed as %, by student's 
paired t-test for variables expressed as means, and by Wilcoxon’s signed rank test for variables expressed as medians    
b P-values for the difference between cases and controls were determined by Chi2-test for variables expressed as %, analysis of variance 
(general linear model) for variables expressed as means, and by the non-parametric Kruskal-Wallis test for variables expressed as 
medians     
23 
 
c Adiponectin measurement was not available in n=16 controls and n=7 cases in EPIC, in n=63 controls and n=56 cases in HPFS, and in 
n=264 controls and n=112 cases in NHS; some study participants had missing values for the here displayed diet and lifestyle factors: in 
EPIC, there were missing values on physical activity (n=69 controls, n=67 cases) and waist circumference (n=65 controls, n=65 cases); in 
HPFS, there were missing values on smoking status (n=7 controls, n=6 cases), waist circumference (n=25 controls, n=46 cases), alcohol 
(n=4 controls, n=5 cases), fiber (n=1 case) or red and processed meat (n=4 controls, n=5 cases) intake; in NHS, there were missing values 
on alcohol (n=8 controls, n=1 cases), fiber (n=11 controls, n=2 cases) and red and processed meat (n=8 controls, n=1 case) intake.  
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Table 2. Association between ADIPOQ SNPs genotyped in EPIC, ADIPOQ allele score and 
plasma adiponectin levels in control participants 
 
   Men and women (n=623) 
SNP  MAF Relative change (95% CI), %a  ptrend F-Value R2 (%) 
rs1063539 G>C 13% 0.9 ( -6.2; 8.6) 0.81 0.1 0.0 
rs16861194 A>G 8% -4.4 (-12.9; 4.8) 0.34 1.0 0.2 
rs12495941 G>T 37% 0.1 ( -5.0; 5.5) 0.96 0.0 0.0 
rs822391 T>C 19% 5.2 ( -1.7; 12.6) 0.14 2.2 0.4 
rs822394 C>A 17% 4.1 ( -2.9; 11.6) 0.26 1.3 0.2 
rs17300539b G>A 9% 18.2 ( 8.5; 28.8) <0.0001 14.5 2.3 
rs17366568b G>A 11% -12.3 (-19.0; -5.0) <0.0001 10.3 1.7 
rs17366743 T>C 3% 20.6 ( 3.0; 41.2) 0.02 5.4 0.9 
rs182052b, c G>A 35% -2.8 ( -7.8; 2.5) 0.29 1.1 0.2 
rs266729b C>G 27% -1.6 ( -7.1; 4.2) 0.59 0.3 0.1 
rs1501299b G>T 28% 6.3 ( 0.3; 12.5) 0.04 4.3 0.7 
rs2241766 T>G 13% 2.3 ( -5.1; 10.3) 0.56 0.3 0.1 
rs3774261 G>A 41% 5.3 ( 0.1; 10.9) 0.05 3.9 0.6 
rs3821799 C>T 47% 0.0 ( -4.9; 5.2) 0.99 0.0 0.0 
ADIPOQ allele score  6.5 ( 3.6; 9.4) <0.0001 20.2 3.2 
MAF: Minor allele frequency; 95% CI, 95% confidence interval 
a Percent change in adiponectin concentrations per copy of minor allele (effect allele) or score 
unit, estimated in univariable linear regression models. 
b incorporated in ADIPOQ allele score for EPIC 
c proxy SNP for rs6810075 
in bold: statistically significant associations (p<0.05) 
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Table 3. Association between all ADIPOQ SNPs genotyped in HPFS and NHS, ADIPOQ allele score and plasma adiponectin levels in 1 
control participants  2 
      Men (n=167), HPFS         Women  (n=510), NHS 
SNP   MAF Rel. change (95% CI), %a ptrend F-Value R2 (%)   SNP   MAF Rel. change (95% CI), %a ptrend F-Value R2 (%) 
rs1063539 G>C 15% -5.6 (-20.0;  11.5) 0.50 0.5 0.3  rs1063539 G>C 12% -1.4 (-9.4;  7.4) 0.75 0.1 0.0 
rs16861194 A>G 9% -1.5 (-19.0;  19.8) 0.88 0.0 0.0  rs16861194 A>G 5% -9.1 ( -19;  1.9) 0.10 2.7 0.5 
rs7615090 T>G 5% -7.4 (-29.0;  20.8) 0.57 0.3 0.2  rs7615090 T>G 6% -7.3 ( -18;  4.8) 0.23 1.5 0.3 
rs822394 C>A 15% -2.3 ( -16.3; 13.9) 0.76 0.1 0.1  rs822394 C>A 17% 6.1 (-1.3; 14.0) 0.11 2.6 0.5 
rs17300539b G>A 9% 13.5 (-5.8; 36.6) 0.19 1.8 1.1  rs17300539b G>A 8% 13.3 ( 2.8; 25.0) 0.01 6.3 1.2 
rs17366568b G>A 8% -9.7 ( -26; 10.1) 0.32 1.0 0.6  rs17366568b G>A 7% -18.5 ( -26.8; -9.2) <0.0001 13.8 2.7 
rs17366743 T>C 3% 0.9 (-26.4;  38.3) 0.96 0.0 0.0  rs17366743 T>C 3% 2.5 ( -11.7; 18.9) 0.75 0.1 0.0 
rs6810075b T>C 33% -11.8 (-21.2;  -1.2) 0.03 4.6 2.7  rs6810075b T>C 31% -5.0 ( -10;  0.7) 0.09 3.0 0.6 
rs6773957 G>A 41% 9.2 (-2.6; 22.3) 0.13 2.3 1.4  rs6773957 G>A 38% 6.5 ( 0.9; 12.5) 0.02 5.2 1.0 
rs822354 G>A 36% 7.6 ( -4.1;  20.9) 0.22 1.5 0.9  rs822354 G>A 33% 1.4 (-4.2;  7.4) 0.62 0.2 0.1 
rs6444175 G>A 28% 11.4 ( -0.7;  25.0) 0.07 3.3 2.0  rs6444175 G>A 27% 7.6 ( 1.2; 14.5) 0.02 5.5 1.1 
rs266717 T>C 49% -3.2 (-13.3;   8.0) 0.56 0.3 0.2  rs266717 T>C 47% -3.8 (-8.8;  1.5) 0.16 2.0 0.4 
rs1426810 A>G 37% 0.7 ( -9.8;  12.4) 0.91 0.0 0.0  rs1426810 A>G 40% 3.9 (-1.7;  9.9) 0.17 1.9 0.4 
rs1342387 T>C 43% 2.9 ( -7.9;  15.0) 0.62 0.3 0.2  rs1342387 T>C 45% -4.4 (-9.5;  1.0) 0.11 2.5 0.5 
rs12733285 C>T 30% -2.7 (-13.7;   9.8) 0.66 0.2 0.1  rs12733285 C>T 30% -4.1 (-9.6;  1.7) 0.16 2.0 0.4 
rs266729b C>G 24% -12.6 (-22.8;  -1.2) 0.03 4.6 2.7  rs266729b C>G 26% -4.4 ( -10;  1.8) 0.16 2.0 0.4 
rs1501299b G>T 26% 13.4 (  1.0;  27.4) 0.04 4.4 2.6  rs1501299b G>T 27% 8.6 ( 2.2; 15.5) 0.01 7.0 1.4 
rs1063538 C>T 41% 9.2 ( -2.6;  22.3) 0.13 2.3 1.4  rs1063538 C>T 38% 6.6 ( 0.9; 12.5) 0.02 5.2 1.0 
rs3774262 G>A 15% -6.0 (-20.0;  10.5) 0.46 0.6 0.3  rs3774262 G>A 11% -0.7 (-9.0;  8.4) 0.88 0.0 0.0 
ADIPOQ allele score 7.7 ( 0.9; 14.9) 0.03 5.0 2.9  ADIPOQ allele score 7.7 (  4.1;  11.3) <0.0001 18.8 3.6 
MAF: Minor allele frequency; 95% CI, 95% confidence interval 3 
a Percent change in adiponectin concentrations per copy of minor allele (effect allele) or score unit, estimated in univariable linear 4 
regression models. 5 
b incorporated in ADIPOQ allele score for HPFS/NHS 6 
in bold: statistically significant associations (p<0.05) 7 
   8 
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Table 4. Association between ADIPOQ allele score and colorectal cancer risk in EPIC, HPFS, and NHS 1 
 2 
  No. Cases/No. Controls 
Relative 
change  
% a OR (95% CI) ptrend phet. 
EPICb 623/623 6.5 0.95 (0.87, 1.03) 0.23  
HPFSc  231/230 7.7 1.00 (0.85, 1.17) 0.97  
NHSc 399/774 7.7 0.98 (0.88, 1.09) 0.73  
Pooled 1253/1627  0.97 (0.91, 1.04) 0.43 0.86 
 3 
a Per score unit, estimates based on univariate linear regression in controls  4 
b Conditional logistic regression, controlling for matching factors (age at blood collection, study center, fasting status, menopausal status 5 
and hormone use in women) 6 
c Unconditional logistic regression, adjusted for matching factors(age at blood draw, date of blood draw) 7 
OR, odds ratio; 95% CI, 95% confidence interval; phet., P value for heterogeneity by study 8 
 9 
 10 
 11 
 12 
Table 5. Instrumental variable estimation of the association between genetically determined adiponectin concentrations with risk of 13 
colorectal cancer in EPIC, HPFS, and NHS (ADIPOQ allele score as instrumental variable) 14 
  15 
 No. Cases/No. Controls IV-OR (95% CI) ptrend phet. 
EPIC 623/623 0.61 (0.25, 1.49) 0.28  
HPFS  231/230 0.90 (0.21, 3.84) 0.89  
NHS 399/774 0.83 (0.31, 2.22) 0.71  
Pooled 1253/1627 0.73 (0.40, 1.34) 0.31 0.86 
IV-OR, instrumental variable odds ratio; 95% CI, 95% confidence interval; phet., P value for heterogeneity by study 16 
IV-OR derived from two-stage regression. First stage was a linear regression. In EPIC, the second stage was a conditional logistic 17 
regression controlling for matching factors (age at blood collection, study center, fasting status, menopausal status and hormone use in 18 
27 
 
women); in HPFS and NHS, the second stage was an unconditional logistic regression adjusting for matching factors (age at blood draw, 1 
date of blood draw) 2 
 3 
phet., P value for heterogeneity by study 4 
          5 
